Rouleau Isabelle, Issa Kana Kode Djogo Nyazy, Zafack Joseline Guetsop, Viger Yv Bonnier, De Serres Gaston
CHU de Québec-Université Laval Research Center, Quebec, QC, G1V 4G2, Canada; Department of Social and Preventive Medicine, Laval University, Quebec, QC, G1V 0A6, Canada; Quebec National Institute of Public Health (INSPQ), Quebec QC, G1V 5B3, Canada.
Department of Social and Preventive Medicine, Laval University, Quebec, QC, G1V 0A6, Canada; Centre for Immunization Surveillance and Programs, Public Health Agency of Canada, Ottawa, ON, K1A 0K9, Canada.
Vaccine. 2025 May 31;57:127217. doi: 10.1016/j.vaccine.2025.127217. Epub 2025 May 8.
In Canada, anesthesia/paresthesia were the most frequently reported adverse events following immunization (AEFI) against SARS-CoV-2. This study aims to describe the frequency and characteristics of anesthesia/paresthesia cases temporally associated with a first or second dose of COVID-19 vaccines administered in Quebec, Canada.
Cases were extracted among AEFI reports submitted to the passive surveillance system. Sociodemographic, vaccination and AEFI information were obtained from the immunization registry. Signs, symptoms and anatomical location were manually extracted from clinical narratives.
From December 13, 2020 to December 31, 2022, 15.2 million doses of vaccines were administered in Quebec. By July 1, 2022, 1024 cases of anesthesia/paresthesia following COVID-19 vaccination had been reported. The global reporting rate was 7.7 per 100,000 doses administered. Rates were higher with the first than the second dose (11.4 vs. 3.8 per 100,000 doses), and higher with ChAdOx1 than with mRNA vaccines Comirnaty™ (BNT-162b2, Pfizer BioNTech) or Spikevax™ (mRNA-1273, Moderna) (28.7 vs. 6.1 and 7.9, respectively). Rates were 3- to 4-times higher in women, with the highest rate ratios among those 18-49 years of age. Median time to onset was 24 h (IQR: 3-96). Paresthesia, hypoesthesia/anesthesia (83 %) were more common than dysesthesias (13 %). Symptoms were reported mostly in upper limbs (62 %), but also frequently in lower limbs (47 %) or the face (42 %). Most reported mild (41 %) or moderate (48 %) symptoms, with a median duration of 5 days (IQR: 2-15), although symptoms lasting 1-5 months (12 %) or over 6 months (1 %) were also reported.
Symptoms of anesthesia/paresthesia are commonly reported following the administration of several vaccines, including those against COVID-19. In most instances, symptoms occur shortly after vaccination, have a limited impact on daily activities, and resolve spontaneously within a month of onset. A small proportion of cases report sensory and/or motor symptom of longer duration, which remain undiagnosed following neurological investigations. Despite being a common occurrence, post-vaccination sensory disturbances remain a poorly understood phenomenon that warrants further study.
在加拿大，麻醉/感觉异常是接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗后最常报告的不良事件。本研究旨在描述在加拿大魁北克省接种第一剂或第二剂2019冠状病毒病（COVID-19）疫苗后暂时出现的麻醉/感觉异常病例的频率和特征。
从提交给被动监测系统的不良事件报告中提取病例。社会人口统计学、疫苗接种和不良事件信息从免疫登记处获取。体征、症状和解剖位置从临床记录中手动提取。
2020年12月13日至2022年12月31日，魁北克省共接种了1520万剂疫苗。截至2022年7月1日，已报告1024例COVID-19疫苗接种后麻醉/感觉异常病例。总体报告率为每10万剂接种量7.7例。第一剂疫苗后的报告率高于第二剂（每10万剂分别为11.4例和3.8例），腺病毒载体疫苗ChAdOx1后的报告率高于信使核糖核酸（mRNA）疫苗Comirnaty™（BNT-162b2，辉瑞生物科技公司）或Spikevax™（mRNA-1273，莫德纳公司）（分别为28.7例、6.1例和7.9例）。女性的报告率高出3至4倍，18至49岁人群中的比率最高。发病的中位时间为24小时（四分位间距：3至96小时）。感觉异常、感觉减退/麻醉（83%）比感觉障碍（13%）更常见。症状大多报告在上肢（62%），但也经常出现在下肢（47%）或面部（42%）。大多数报告的症状为轻度（41%）或中度（48%），中位持续时间为5天（四分位间距：2至15天），不过也有报告症状持续1至5个月（12%）或超过6个月（1%）。
在接种包括COVID-19疫苗在内的几种疫苗后，常见麻醉/感觉异常症状的报告。在大多数情况下，症状在接种疫苗后不久出现，对日常活动影响有限，并在发病后一个月内自行缓解。一小部分病例报告了持续时间较长的感觉和/或运动症状，经神经学检查后仍未确诊。尽管接种疫苗后感觉障碍很常见，但仍是一种了解不足的现象，值得进一步研究。
